ArticleRheumatology (Oxford, England)2025
Shared molecular profiles of anti-PL12 autoantibodies in anti-synthetase syndrome.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesAnti-PL12 autoantibodies are targeted against alanyl-tRNA synthetase, a cytosolic enzyme which plays a vital role in protein synthesis. Clinically, such antibodies are strongly associated with interstitial lung disease and confer a poor prognosis. To better understand their molecular composition, anti-PL12 immunoglobulin variable region subfamily expression and their mutational signatures were analysed by mass spectrometry (MS)-based proteomics to provide insights into personalized molecular diagnosis.
methodsPatients with anti-PL12 autoantibodies were identified from routine myositis immunoblots. Serum anti-PL12 IgG autoantibodies were then purified from specific anti-PL12 precipitins using conventional counter-immunoelectrophoresis. Immunoglobulin (Ig) heavy and light-chains were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), digested by enzymes and profiled by MS sequencing for immunoglobulin variable region (IgV) subfamily usage and somatic hypermutation analysis.
resultsTen patients were identified; seven females and three males with an average age of 65 years. All had lung disease, while two had concurrent myositis. MS sequencing of precipitating anti-PL12 IgGs revealed an oligoclonal repertoire with shared expression of IGHV3-23-encoded heavy chain and IGKV3-20- and IGKV1-27-encoded light chains. Furthermore, shared IgV somatic hypermutations were observed across unrelated patients in both heavy and light chain, in regions likely to be antigen interacting.
conclusionAnti-PL12 autoantibodies among different patients show highly convergent sequences and variable region composition. The inter-individual similarity reveals the evolutionary process towards specific, presumably immuno-dominant, epitopes on PL12 during antigen-driven clonal selection. These unique anti-PL12 autoantibody molecular signatures have the potential to be valuable biomarkers when compared with the simple readout of conventional immunoassays.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.